IceCure Receives 180-Day Extension from Nasdaq for Bid Compliance

IceCure Granted 180-Day Extension by Nasdaq

IceCure Medical Ltd., a prominent developer of minimally-invasive cryoablation technology, has received a significant update regarding its compliance status with Nasdaq. On May 12, 2026, the company was notified that it has been granted an additional 180-day period to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This extension is crucial for the company as it seeks to stabilize its market position.

Nasdaq's decision came after IceCure demonstrated its commitment to meeting other listing requirements, excluding the bid price. The company's market value of publicly held shares met the necessary criteria, allowing IceCure to qualify for a compliance extension. This period provides the company until November 9, 2026, to rectify the bid price issue.

Previously, Nasdaq had informed IceCure on November 12, 2025, that its ordinary shares did not meet the minimum bid price requirement, which necessitated a compliance period of 180 days. After failing to comply within that timeframe, IceCure promptly requested an additional compliance period, which Nasdaq has now granted.

According to Nasdaq's notification, if IceCure's ordinary shares reach at least $1.00 per share for a minimum of ten consecutive business days before the deadline, the company will regain compliance and this matter will be closed. However, Nasdaq retains the right to require the company to maintain this price for a longer duration, up to twenty consecutive business days, to ensure long-term compliance.

Despite the challenges, it's important to note that this announcement does not induce any immediate changes in the trading or listing status of IceCure’s shares, which will continue to be traded on the Nasdaq Capital Market under the symbol